A Phase III Randomized Controlled Clinical Study Comparing BL-B01D1 With Platinum Based Chemotherapy (First-line of Systemic Treatment) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer After EGFR-TKI Failure.

This document provides information about a clinical trial for the treatment of non-squamous non-small cell lung cancer. The trial involves the use of a drug called BL-B01D1, which is administered in combination with either Pemetrexed+Cisplatin or Carboplatin. Participants who experience clinical benefit may receive additional treatment. The trial is currently in the recruitment phase and aims to enroll 428 participants, with an estimated completion date of May 2026. The study is being conducted in China by Sichuan Baili Pharmaceutical Co., Ltd. and Baili-Bio (Chengdu) Pharmaceutical Co., Ltd., with Li Zhang from Sun Yat-sen University as the principal investigator. [Extracted from the article]